Hans Henrik D. Parving
#124,978
Most Influential Person Across History
Hans Henrik D. Parving's AcademicInfluence.com Rankings
Download Badge
Philosophy
Hans Henrik D. Parving's Degrees
- Doctorate Medicine University of Copenhagen
- PhD Medicine University of Copenhagen
Why Is Hans Henrik D. Parving Influential?
(Suggest an Edit or Addition)Hans Henrik D. Parving's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. (2001) (5071)
- Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. (2003) (4290)
- The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. (2001) (3174)
- Effect of a multifactorial intervention on mortality in type 2 diabetes. (2008) (3152)
- Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. (2002) (1883)
- Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. (2009) (1786)
- Cardiorenal end points in a trial of aliskiren for type 2 diabetes. (2012) (1133)
- A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. (2009) (1106)
- Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. (2004) (956)
- Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study (1999) (946)
- EARLY AGGRESSIVE ANTIHYPERTENSIVE TREATMENT REDUCES RATE OF DECLINE IN KIDNEY FUNCTION IN DIABETIC NEPHROPATHY (1983) (912)
- Aliskiren combined with losartan in type 2 diabetes and nephropathy. (2008) (841)
- Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. (2013) (796)
- Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy (2004) (746)
- Nephropathy in diabetes. (2004) (698)
- Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial (2010) (678)
- Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. (2002) (672)
- Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. (2011) (645)
- Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. (1982) (613)
- Prevention of diabetic renal disease with special reference to microalbuminuria (1995) (567)
- Effect of antihypertensive treatment on kidney function in diabetic nephropathy. (1987) (563)
- Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). (2003) (495)
- Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. (1991) (482)
- Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. (2006) (479)
- Prevalence of microalbuminuria, arterial hypertension, retinopathy, and neuropathy in patients with insulin dependent diabetes (1988) (461)
- Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study (1996) (458)
- Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. (1992) (443)
- Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study (1997) (428)
- Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials (2008) (425)
- Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial (2008) (417)
- Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study (2004) (410)
- Albuminuria and Poor Glycemic Control Predict Mortality in NIDDM (1995) (379)
- Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. (2003) (373)
- Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial (2016) (369)
- Progression of nephropathy in type 2 diabetic patients. (2004) (355)
- Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. (1988) (347)
- Microalbuminuria as an early marker for cardiovascular disease. (2006) (345)
- Is diabetic nephropathy an inherited complication? (1992) (330)
- Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. (1986) (312)
- Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. (2009) (311)
- The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. (1994) (310)
- Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial (2019) (306)
- Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. (2007) (305)
- Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. (2000) (296)
- Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. (2002) (291)
- An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. (2011) (287)
- Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. (2005) (282)
- Progression of diabetic nephropathy. (2001) (255)
- Transcapillary Escape Rate of Albumin and Plasma Volume in Essential Hypertension (1973) (250)
- New Susceptibility Loci Associated with Kidney Disease in Type 1 Diabetes (2012) (250)
- Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. (2003) (248)
- Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. (2005) (246)
- Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. (2002) (245)
- Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. (2003) (240)
- Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications (2005) (237)
- Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. (2009) (236)
- Diabetic nephropathy: prevention and treatment. (2001) (226)
- Beneficial impact of spironolactone in diabetic nephropathy. (2005) (219)
- The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. (2014) (217)
- Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. (2002) (215)
- Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. (2003) (215)
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. (2016) (214)
- Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. (2004) (214)
- Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. (2012) (213)
- Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes (2011) (213)
- Aldosterone escape during blockade of the renin–angiotensin–aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate (2004) (212)
- Prognosis in diabetic nephropathy. (1989) (206)
- Lack of Relationship Between an Insertion/Deletion Polymorphism in the Angiotensin I–Converting Enzyme Gene and Diabetic Nephropathy and Proliferative Retinopathy in IDDM Patients (1995) (206)
- Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. (2006) (203)
- Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. (2004) (201)
- Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy. (1989) (196)
- Prevalence of Arterial Hypertension in Diabetic Patients Before and After the JNC-V (1994) (195)
- Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria (1999) (189)
- Diabetic nephropathy: can renoprotection be extrapolated to cardiovascular protection? (2002) (183)
- Long-Term Effect of Lisinopril and Atenolol on Kidney Function in Hypertensive NIDDM Subjects With Diabetic Nephropathy (1997) (181)
- Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment: A Post Hoc Analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial (2011) (174)
- Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. (2006) (167)
- Evidence for Diabetic Encephalopathy (1991) (164)
- Comparison of different measures of urinary protein excretion for prediction of renal events. (2010) (163)
- Glomerular Structure and Function in Diabetic Nephropathy: Early to Advanced Stages (1990) (162)
- Vitamin D Levels and Mortality in Type 2 Diabetes (2010) (159)
- Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria (2009) (153)
- Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. (2006) (152)
- Renoprotection in diabetes: genetic and non-genetic risk factors and treatment (1998) (150)
- Impact of Arterial Blood Pressure and Albuminuria on the Progression of Diabetic Nephropathy in IDDM Patients (1993) (149)
- Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus (2007) (147)
- Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. (1999) (145)
- Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. (2000) (144)
- Unchanged Incidence of Diabetic Nephropathy in IDDM Patients (1995) (144)
- Cost-Effectiveness of Intensified Versus Conventional Multifactorial Intervention in Type 2 Diabetes (2008) (137)
- Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. (2008) (136)
- The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) (2000) (135)
- Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. (2008) (135)
- Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. (2002) (134)
- Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. (2005) (131)
- Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. (1999) (130)
- Serum Uric Acid as a Predictor for Development of Diabetic Nephropathy in Type 1 Diabetes (2009) (126)
- Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. (2011) (125)
- Causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy. (2000) (125)
- Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. (2011) (124)
- Subclinical Coronary and Aortic Atherosclerosis Detected by Magnetic Resonance Imaging in Type 1 Diabetes With and Without Diabetic Nephropathy (2006) (124)
- Association between Mannose‐Binding Lectin and Vascular Complications in Type 1 Diabetes (2004) (124)
- Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals (2010) (123)
- Excess mortality associated with diuretic therapy in diabetes mellitus. (1992) (122)
- Vitamin D Levels, Microvascular Complications, and Mortality in Type 1 Diabetes (2011) (120)
- Markers of Endothelial Dysfunction and Inflammation in Type 1 Diabetic Patients With or Without Diabetic Nephropathy Followed for 10 Years (2008) (120)
- Neutrophil Gelatinase‐Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross‐sectional study and the effects of lisinopril (2010) (119)
- Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. (2005) (118)
- Double‐blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in Type 2 diabetic patients (2001) (117)
- Diabetic Nephropathy and Arterial Hypertension: The Effect of Antihypertensive Treatment (1983) (117)
- Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes (2010) (116)
- Expression, localization, and function of the thioredoxin system in diabetic nephropathy. (2009) (115)
- Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study. (2005) (114)
- Association between mannose-binding lectin and vascular complications in type 1 diabetes. (2004) (114)
- Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. (2006) (114)
- Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. (1998) (112)
- Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. (2015) (112)
- Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study (2011) (111)
- Pregnancy and progression of diabetic nephropathy (2002) (110)
- Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. (1993) (109)
- Initiation and progression of diabetic nephropathy. (1996) (109)
- Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy (2010) (107)
- Urinary Liver-Type Fatty Acid-Binding Protein Predicts Progression to Nephropathy in Type 1 Diabetic Patients (2010) (107)
- Glomerular structure and function in proteinuric Type 2 (non-insulin-dependent) diabetic patients (1993) (106)
- Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria (2004) (104)
- A Nation‐wide Cross‐sectional Study of Urinary Albumin Excretion Rate, Arterial Blood Pressure and Blood Glucose Control in Danish Children with Type 1 Diabetes Mellitus (1990) (104)
- Reduction in albuminuria predicts diminished progression in diabetic nephropathy. (1994) (102)
- Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study (2007) (102)
- Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment (1994) (102)
- QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes (2000) (101)
- Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients. (1997) (101)
- Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes (2006) (101)
- Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. (2001) (101)
- Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. (2001) (100)
- A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy (1981) (99)
- Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience. (1995) (97)
- Low Birth Weight: A Risk Factor for Development of Diabetic Nephropathy? (1995) (96)
- Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. (2011) (96)
- Genetic variation in the Renin-Angiotensin system and progression of diabetic nephropathy. (2003) (96)
- Progression of diabetic nephropathy in normotensive type 1 diabetic patients. (1999) (94)
- On the Mechanisms of Blunted Nocturnal Decline in Arterial Blood Pressure in NIDDM Patients With Diabetic Nephropathy (1995) (94)
- Endothelial dysfunction and low‐grade inflammation and the progression of retinopathy in Type 2 diabetes (2007) (93)
- Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and re (2004) (92)
- Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. (2005) (92)
- The course of kidney function in Type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy (1993) (91)
- Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. (2008) (91)
- A Single Nucleotide Polymorphism within the Acetyl-Coenzyme A Carboxylase Beta Gene Is Associated with Proteinuria in Patients with Type 2 Diabetes (2010) (90)
- Impact of Blood Pressure and Antihypertensive Treatment on Incipient and Overt Nephropathy, Retinopathy, and Endothelial Permeability in Diabetes Mellitus (1991) (89)
- Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. (1998) (88)
- Analysis of 14 Candidate Genes for Diabetic Nephropathy on Chromosome 3q in European Populations (2006) (88)
- Glomerular permselectivity in early stages of overt diabetic nephropathy. (2000) (88)
- Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. (2014) (88)
- Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. (1995) (87)
- Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. (2005) (86)
- Evolving strategies for renoprotection: diabetic nephropathy (2001) (86)
- Microalbuminuria: a parameter that has changed diabetes care. (2015) (86)
- Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. (2012) (86)
- Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. (1999) (86)
- Optimal dose of losartan for renoprotection in diabetic nephropathy. (2002) (85)
- Mannose-binding lectin and mortality in type 2 diabetes. (2006) (85)
- Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. (2000) (85)
- The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality (2007) (84)
- Telomere length predicts all-cause mortality in patients with type 1 diabetes (2009) (83)
- Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study (2008) (83)
- Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. (2017) (82)
- Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study (2008) (81)
- DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. (2008) (81)
- Effects of insulin on kidney function and sodium excretion in healthy subjects (1989) (80)
- Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin Alfa: The Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Experience (2011) (80)
- ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. (2008) (79)
- Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. (1998) (79)
- Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON) (2013) (79)
- Raised Serum Sialic Acid Concentration in NIDDM Patients With and Without Diabetic Nephropathy (1996) (79)
- Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes. (2011) (77)
- Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria (2006) (76)
- Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. (2000) (76)
- Elevated levels of high-molecular-weight adiponectin in type 1 diabetes. (2008) (76)
- Diabetic nephropathy and arterial hypertension (2004) (75)
- Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy (1996) (75)
- Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study. (2005) (75)
- Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study. (2003) (74)
- Anaemia in diabetes: is there a rationale to TREAT? (2006) (74)
- Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: case-control, haplotype, and family-based study in three European populations. (2007) (74)
- Angiotensinogen Gene Polymorphisms in IDDM Patients With Diabetic Nephropathy (1996) (73)
- Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease (2019) (73)
- Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo‐controlled crossover study (2012) (73)
- Impact of Lisinopril and Atenolol on Kidney Function in Hypertensive NIDDM Subjects With Diabetic Nephropathy (1994) (72)
- Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). (2011) (72)
- Polymorphism screening of four genes encoding advanced glycation end-product putative receptors. Association study with nephropathy in type 1 diabetic patients. (2001) (71)
- Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study (2016) (70)
- Smoking and progression of diabetic nephropathy in type 1 diabetes. (2003) (70)
- Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria (2010) (70)
- Cataract surgery on diabetic patients. A prospective evaluation of risk factors and complications. (2002) (70)
- Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). (2009) (69)
- Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy (2008) (68)
- Serum uric acid as a new player in the development of diabetic nephropathy. (2011) (68)
- Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) (2012) (68)
- Fish Oil in Diabetic Nephropathy (1996) (67)
- Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. (2014) (67)
- Low-protein diet and kidney function in insulin-dependent diabetic patients with diabetic nephropathy. (1999) (67)
- Early renin‐angiotensin system intervention is more beneficial than late intervention in delaying end‐stage renal disease in patients with type 2 diabetes (2016) (67)
- Remission of nephrotic-range albuminuria in type 1 diabetic patients. (2001) (67)
- Tubular and Glomerular Injury in Diabetes and the Impact of ACE Inhibition (2009) (67)
- Effects of Long‐term Antihypertensive Treatment on Kidney Function in Diabetic Nephropathy (1985) (65)
- Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria (2011) (65)
- Improved Survival and Renal Prognosis of Patients With Type 2 Diabetes and Nephropathy With Improved Control of Risk Factors (2014) (64)
- Glomerular hyperfiltration in microalbuminuric NIDDM patients (1996) (64)
- Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study (2018) (63)
- Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). (2009) (63)
- Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes (2019) (63)
- Cholesterol-lowering therapy may retard the progression of diabetic nephropathy (1995) (63)
- Dipyridamole, cold pressor test, and demonstration of endothelial dysfunction: a PET study of myocardial perfusion in diabetes. (2003) (62)
- Differences Between Nisoldipine and Lisinopril on Glomerular Filtration Rates and Albuminuria in Hypertensive IDDM Patients With Diabetic Nephropathy During the First Year of Treatment (1997) (62)
- The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics (2005) (62)
- Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? (2003) (62)
- Early changes in diabetic retinopathy: Capillary loss and blood‐retina barrier permeability in relation to metabolic control (1994) (61)
- Microalbuminuria in essential hypertension and diabetes mellitus (1996) (61)
- Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy (2018) (60)
- Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. (2000) (60)
- Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial (2010) (60)
- Renal function and structure in albuminuric type 2 diabetic patients without retinopathy. (2001) (60)
- A combined abnormality in heart rate variation and QT corrected interval is a strong predictor of cardiovascular death in type 1 diabetes (2008) (60)
- Impaired autoregulation of glomerular filtration rate in Type 1 (insulin-dependent) diabetic patients with nephropathy (1984) (60)
- Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy. (2000) (60)
- Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT). (2014) (59)
- Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy (1992) (59)
- Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy (2004) (59)
- Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. (2011) (59)
- Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy (2004) (59)
- Improved prognosis of diabetic nephropathy in type 1 diabetes. (2015) (59)
- Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and Nephropathy (2010) (59)
- Circadian rhythm of arterial blood pressure and albuminuria in diabetic nephropathy. (1996) (58)
- Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. (2004) (58)
- Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients (2005) (58)
- Kidney Function During and After Withdrawal of Long-Term Irbesartan Treatment in Patients With Type 2 Diabetes and Microalbuminuria (2003) (57)
- A strong correlation between glomerular filtration rate and filtration surface in diabetic nephropathy (1988) (57)
- Prevalence of microalbuminuria in children with Type 1 (insulin-dependent) diabetes mellitus (1986) (56)
- Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy (1996) (56)
- Genetic Examination of SETD7 and SUV39H1/H2 Methyltransferases and the Risk of Diabetes Complications in Patients With Type 1 Diabetes (2011) (56)
- Osteoprotegerin and Mortality in Type 2 Diabetic Patients (2010) (56)
- Plasma renin and prorenin and renin gene variation in patients with insulin-dependent diabetes mellitus and nephropathy. (1999) (55)
- Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial (2016) (55)
- Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria. (2016) (54)
- [The Steno-2 study. Intensive multifactorial intervention reduces the occurrence of cardiovascular disease in patients with type 2 diabetes]. (2003) (54)
- Diabetes and end stage renal disease (2000) (54)
- Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease in Individuals With Type 1 Diabetes: A 12-Year Follow-up Study (2017) (54)
- Increased microvascular permeability to plasma proteins in short- and long-term juvenile diabetics. (1976) (54)
- Short stature and diabetic nephropathy (1995) (53)
- G/T Substitution in Intron 1 of the UNC13B Gene Is Associated With Increased Risk of Nephropathy in Patients With Type 1 Diabetes (2008) (52)
- Vitamin D Levels and Asymptomatic Coronary Artery Disease in Type 2 Diabetic Patients With Elevated Urinary Albumin Excretion Rate (2011) (52)
- Insulin analogues and severe hypoglycaemia in type 1 diabetes. (2012) (52)
- Left Ventricular Hypertrophy in Non‐insulin‐dependent Diabetic Patients With and Without Diabetic Nephropathy (1997) (52)
- Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy. (2018) (52)
- Effect of a Multifactorial Intervention on Mortality in Type II Diabetes (2008) (51)
- Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. (2005) (50)
- Microalbuminuria as an early indicator of osteopenia in male insulin‐dependent diabetic patients (1997) (49)
- Reduced Albuminuria During Early and Aggressive Antihypertensive Treatment of Insulin-dependent Diabetic Patients with Diabetic Nephropathy (1981) (49)
- Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study (2017) (48)
- Diurnal variations of glomerular filtration rate and albuminuria in diabetic nephropathy. (2002) (48)
- Angiotensin-II type 1 receptor gene polymorphism and diabetic microangiopathy. (1996) (48)
- The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1 (2013) (47)
- Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy. (2006) (46)
- Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy. (2000) (46)
- Does microalbuminuria predict diabetic nephropathy? (2002) (46)
- Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. (2005) (45)
- Increased Metabolic Turnover Rate and Transcapillary Escape Rate of Albumin in Essential Hypertension (1974) (45)
- Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review (2016) (45)
- SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes (2014) (45)
- Elevated Urinary Prostaglandin Excretion and the Effect of Indomethacin on Renal Function in Incipient Diabetic Nephropathy (1988) (44)
- Microalbuminuria in type 1 and type 2 diabetes mellitus: Evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy (2002) (44)
- Impaired autoregulation of the glomerular filtration rate in patients with nondiabetic nephropathies. (1999) (44)
- Prevalence of hyperglycaemia and undiagnosed diabetes mellitus in patients with acute myocardial infarction. (2009) (44)
- The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. (2015) (44)
- Increased serum concentration of von Willebrand factor in non-insulin dependent diabetic patients with and without diabetic nephropathy (1995) (43)
- Effects of hyperglycaemia on kidney function, atrial natriuretic factor and plasma renin in patients with insulin-dependent diabetes mellitus. (1991) (42)
- Arterial stiffness and endothelial dysfunction independently and synergistically predict cardiovascular and renal outcome in patients with type 1 diabetes (2012) (42)
- Reduced Urinary Excretion of Epidermal Growth Factor in Incipient and Overt Diabetic Nephropathy (1989) (42)
- Diabetic microvascular complications are not associated with two polymorphisms in the GLUT-1 and PC-1 genes regulating glucose metabolism in Caucasian type 1 diabetic patients. (2001) (42)
- Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study (2005) (42)
- Red cell Na+/Li+ countertransport in non-insulin-dependent diabetics with diabetic nephropathy. (1991) (41)
- Effect of insulin on renal sodium handling in hyperinsulinaemic Type 2 (non-insulin-dependent) diabetic patients with peripheral insulin resistance (1991) (41)
- PGC-1α Gly482Ser Polymorphism Associates With Hypertension Among Danish Whites (2005) (41)
- Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes (2009) (41)
- CCTTT-repeat polymorphism in the human NOS2-promoter confers low risk of diabetic nephropathy in type 1 diabetic patients. (2000) (40)
- Are human endogenous retroviruses triggers of autoimmune diseases? Unveiling associations of three diseases and viral loci (2015) (39)
- Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial (2009) (39)
- Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? (2002) (39)
- Targeting hyperglycaemia with either metformin or repaglinide in non‐obese patients with type 2 diabetes: results from a randomized crossover trial (2007) (39)
- On the pathogenesis of arterial blood pressure elevation early in the course of diabetic nephropathy. (1989) (39)
- Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. (2004) (38)
- Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and Microalbuminuria (2018) (38)
- Improved visual function in IDDM patients with unchanged cumulative incidence of sight-threatening diabetic retinopathy. (1998) (38)
- Plasma alpha-defensin is associated with cardiovascular morbidity and mortality in type 1 diabetic patients. (2008) (38)
- The Selective Vitamin D Receptor Activator for Albuminuria Lowering (VITAL) Study: Study Design and Baseline Characteristics (2009) (38)
- European rational approach for the genetics of diabetic complications--EURAGEDIC: patient populations and strategy. (2007) (38)
- White Coat Hypertension in NIDDM Patients With and Without Incipient and Overt Diabetic Nephropathy (1997) (37)
- Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial (2011) (37)
- Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria (2017) (36)
- Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes (2015) (36)
- Effect of antihypertensive treatment on blood-retinal barrier permeability to fluorescein in hypertensive Type 1 (insulin-dependent) diabetic patients with background retinopathy (1989) (36)
- High YKL-40 levels predict mortality in patients with type 2 diabetes. (2012) (36)
- Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial (2010) (36)
- Increased renal gene transcription of protein kinase C-β in human diabetic nephropathy: relationship to long-term glycaemic control (2008) (36)
- Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. (2008) (36)
- Pathophysiological aspects of edema formation in diabetic nephropathy. (1990) (36)
- Epicardial, pericardial and total cardiac fat and cardiovascular disease in type 2 diabetic patients with elevated urinary albumin excretion rate (2017) (35)
- Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial (2008) (35)
- Prevalence of left ventricular hypertrophy in Type I diabetic patients with diabetic nephropathy (1999) (35)
- Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy. (1997) (34)
- Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. (2016) (34)
- Endothelin and von Willebrand factor as parameters of endothelial function in idiopathic dilated cardiomyopathy: different stimuli for release before and after heart transplantation? (1999) (34)
- Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled diabetic retinopathy candesartan trials (2011) (34)
- Poor prognosis in proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study. (2005) (34)
- Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers (2016) (33)
- Remission and regression of diabetic nephropathy (2004) (33)
- Effects of indomethacin on kidney function in Type 1 (insulin-dependent) diabetic patients with nephropathy (1987) (32)
- Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone. (2005) (32)
- Soluble CD40 ligand is elevated in Type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function (2010) (32)
- Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. (2015) (32)
- The acute effect of smoking on systemic haemodynamics, kidney and endothelial functions in insulin-dependent diabetic patients with microalbuminuria. (1996) (31)
- Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy (2004) (31)
- Nephropathy in Type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity (2009) (31)
- Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria (2018) (31)
- Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up study (2012) (30)
- Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study. (2003) (30)
- Increased blood pressure and erythrocyte sodium/lithium countertransport activity are not inherited in diabetic nephropathy (1990) (30)
- Relationship Between Blood Pressure and Urinary Albumin Excretion Rate in Young Danish Type 1 Diabetic Patients: Comparison to Non‐diabetic Children (1994) (30)
- Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy. (2000) (30)
- Total plasma homocysteine is associated with hypertension in Type I diabetic patients (2002) (30)
- Diabetic nephropathy. (2003) (30)
- Autoregulation of glomerular filtration rate in patients with type 2 diabetes during isradipine therapy. (2003) (30)
- Microalbuminuria and obesity: impact on cardiovascular disease and mortality (2009) (30)
- IGFBP-4 Fragments as Markers of Cardiovascular Mortality in Type 1 Diabetes Patients With and Without Nephropathy. (2015) (30)
- Association of aldose reductase gene Z+2 polymorphism with reduced susceptibility to diabetic nephropathy in Caucasian Type 1 diabetic patients (2004) (30)
- Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies (2017) (30)
- The impact of hypertension and antihypertensive treatment on the course and prognosis of diabetic nephropathy. (1990) (30)
- Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. (1996) (29)
- Renoprotection with and without blood pressure reduction. (2005) (29)
- Apolipoprotein(a) in insulin-dependent diabetic patients with and without diabetic nephropathy. (1992) (29)
- Monitoring kidney function in diabetic nephropathy (1994) (29)
- SNP in the genome-wide association study hotspot on chromosome 9p21 confers susceptibility to diabetic nephropathy in type 1 diabetes (2012) (29)
- Probenecid inhibition of the outward transport of fluorescein across the human blood‐retina barrier (1994) (29)
- The Importance of Short‐Term Off‐Target Effects in Estimating the Long‐Term Renal and Cardiovascular Protection of Angiotensin Receptor Blockers (2014) (29)
- Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate. (2011) (29)
- Polymorphisms in the Interleukin-1 Gene Cluster Do Not Contribute to the Genetic Susceptibility of Diabetic Nephropathy in Caucasian Patients With IDDM (1997) (29)
- Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin? (2013) (28)
- Lack of synergism between long-term poor glycaemic control and three gene polymorphisms of the renin angiotensin system on risk of developing diabetic nephropathy in Type I diabetic patients (2000) (28)
- Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes – An observational follow-up study (2018) (28)
- Long-term prevention of diabetic nephropathy: an audit (2008) (28)
- Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. (2003) (28)
- An Extension of the Early Treatment Diabetic Retinopathy Study (ETDRS) System for Grading of Diabetic Macular Edema in the Astemizole Retinopathy Trial (2006) (27)
- Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1. (2001) (27)
- NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis (2011) (27)
- Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy? (2006) (27)
- Hypotensive Therapy Reduces Microvascular Albumin Leakage in Insulin‐dependent Diabetic Patients with Nephropathy (1986) (27)
- Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. (2009) (27)
- The impact of glycaemic control on autoregulation of glomerular filtration rate in patients with non-insulin dependent diabetes. (2001) (27)
- Trisomy 8 syndrome (1977) (26)
- The prevalence of coeliac disease in adult Danish patients with type 1 diabetes with and without nephropathy (2005) (26)
- The PPAR gamma 2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy. (2008) (26)
- A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers (2014) (26)
- Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction? (2006) (25)
- A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus (2010) (25)
- [Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno-2 study]. (1999) (25)
- Course of glomerular filtration rate in albuminuric type 2 diabetic patients with or without diabetic glomerulopathy. (2000) (25)
- PGC-1alpha Gly482Ser polymorphism associates with hypertension among Danish whites. (2005) (25)
- Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy. (2015) (25)
- Renal protection in diabetes: an emerging role for calcium antagonists (1996) (25)
- Beneficial Impact of Ramipril on Left Ventricular Hypertrophy in Normotensive Nonalbummuric NIDDM Patients (1998) (25)
- Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease (2013) (24)
- Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies (2007) (24)
- Left ventricular hypertrophy in normoalbuminuric type 2 diabetic patients not taking antihypertensive treatment. (2005) (24)
- PC-1 amino acid variant (K121Q) has no impact on progression of diabetic nephropathy in type 1 diabetic patients. (2002) (24)
- Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria (2016) (23)
- Plasma volume, intravascular albumin and its transcapillary escape rate in patients with extensive skin disease (1976) (23)
- Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients (2018) (23)
- Agreement between fasting and postprandial LDL cholesterol measured with 3 methods in patients with type 2 diabetes mellitus. (2011) (23)
- High blood pressure is a major factor in progression of diabetic nephropathy. (1988) (23)
- Quantitative studies of glomerular ultrastructure in human and experimental diabetes. (1984) (23)
- [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]. (2001) (23)
- Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. (2013) (23)
- Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria (2020) (23)
- Association of the pattern recognition molecule H-ficolin with incident microalbuminuria in an inception cohort of newly diagnosed type 1 diabetic patients: an 18 year follow-up study (2014) (23)
- THE BLOOD‐RETINAL BARRIER PERMEABILITY IN ESSENTIAL HYPERTENSION (1983) (22)
- Serum amyloid A and C-reactive protein levels may predict microalbuminuria and macroalbuminuria in newly diagnosed type 1 diabetic patients. (2013) (22)
- Diabetic hypertensive patients. Is this a group in need of particular care and attention? (1999) (22)
- Calcium antagonists and cardiovascular risk in diabetes. (1998) (22)
- NT‐proBNP by Itself Predicts Death and Cardiovascular Events in High‐Risk Patients With Type 2 Diabetes Mellitus (2020) (22)
- Apolipoprotein(a) and cardiovascular disease in Type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy (1993) (22)
- Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 diabetic patients with microalbuminuria. (2000) (21)
- Effects of acetazolamide on kidney function in Type 1 (insulin-dependent) diabetic patients with diabetic nephropathy (1988) (21)
- Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with type 1 diabetes prone to severe hypoglycaemia: The HypoAna trial. (2016) (21)
- Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients. (2001) (21)
- Increased Plasma Apolipoprotein(a) Levels in IDDM Patients With Diabetic Nephropathy (1996) (20)
- Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). (2019) (20)
- Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen (1995) (20)
- Urinary Neutrophil Gelatinase-Associated Lipocalin and Progression of Diabetic Nephropathy in Type 1 Diabetic Patients in a Four-Year Follow-Up Study (2010) (20)
- The acute effect of acetazolamide on glomerular filtration rate and proximal tubular reabsorption of sodium and water in normal man. (1989) (20)
- Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria (2012) (20)
- Antihypertensive effects of double the maximum dose of valsartan in African–American patients with type 2 diabetes mellitus and albuminuria (2010) (20)
- Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy. (2017) (20)
- Higher plasma soluble receptor for advanced glycation endproducts (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-yr follow-up study (2010) (20)
- Natural course of kidney function in Type 2 diabetic patients with diabetic nephropathy (1999) (19)
- Polymorphisms in the B-type natriuretic peptide (BNP) gene are associated with NT-proBNP levels but not with diabetic nephropathy or mortality in type 1 diabetic patients. (2007) (19)
- The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP (2012) (19)
- Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20 year life-course study in an inception cohort (2017) (19)
- Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes. (2011) (19)
- Elevated Placental Growth Factor (PlGF) Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients with Diabetic Nephropathy (2005) (19)
- Increased Left Ventricular Mass in Normotensive Type 1 Diabetic Patients With Diabetic Nephropathy (1998) (19)
- Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate. (2003) (18)
- Baseline characteristics and enrichment results of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial. (2018) (18)
- Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. (2005) (18)
- NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients (2012) (18)
- Blood‐retina barrier permeability in diabetes during acute ACE‐inhibition (1991) (18)
- Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. (1996) (18)
- Acute reduction of arterial blood pressure reduces urinary albumin excretion in Type 1 (insulin-dependent) diabetic patients with incipient nephropathy (1986) (18)
- Elevated levels of plasma von Willebrand factor and the risk of macro- and microvascular disease in type 2 diabetic patients with microalbuminuria. (2001) (18)
- Plasma NT-proBNP and white matter hyperintensities in type 2 diabetic patients (2012) (18)
- Toe–brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria (2017) (18)
- Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria (2011) (18)
- Effect of Insulin Analogs on Frequency of Non-Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Severe Hypoglycemia: Much Higher Rates Detected by Continuous Glucose Monitoring than by Self-Monitoring of Blood Glucose-The HypoAna Trial. (2018) (18)
- Birth weight – a risk factor for progression in diabetic nephropathy? (2003) (17)
- Stable Glomerular Filtration Rate in Normotensive IDDM Patients With Stable Microalbuminuria: A 5-year prospective study (1997) (17)
- Increased All-Cause Mortality in Patients With Type 1 Diabetes and High-Expression Mannan-Binding Lectin Genotypes: A 12-Year Follow-up Study (2015) (17)
- Direct renin inhibition in chronic kidney disease (2012) (16)
- Renal protection in diabetes--an emerging role for calcium antagonists. (1996) (16)
- Benefits and cost of antihypertensive treatment in incipient and overt diabetic nephropathy. (1998) (16)
- Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus (2016) (16)
- Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy. (1996) (16)
- Beneficial impact on cardiovascular risk factors by dual blockade of the renin-angiotensin system in diabetic nephropathy. (2004) (16)
- Baseline characteristics and enrichment results from the SONAR trial (2018) (16)
- Kidney function after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. (1997) (15)
- Effect of short‐term hyperglycaemia on haemodynamics in type 1 diabetic patients (2003) (15)
- A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design (2012) (15)
- Myocardial perfusion in type 2 diabetes with left ventricular hypertrophy: normalisation by acute angiotensin-converting enzyme inhibition (2004) (15)
- Pregnancy‐associated plasma protein A in a large cohort of Type 1 diabetic patients with and without diabetic nephropathy—a prospective follow‐up study (2007) (15)
- The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy (2017) (15)
- CYP2C9 variant modifies blood pressure‐lowering response to losartan in Type 1 diabetic patients with nephropathy (2007) (15)
- Is antihypertensive treatment the same for NIDDM and IDDM patients? (1998) (15)
- Evaluation of placental growth factor and soluble Fms‐like tyrosine kinase 1 as predictors of all‐cause and cardiovascular mortality in patients with Type 1 diabetes with and without diabetic nephropathy (2012) (15)
- Beneficial impact of intensified multifactorial intervention on risk of stroke: outcome of 21 years of follow-up in the randomised Steno-2 Study (2019) (14)
- A polymorphism in the angiotensin II type 1 receptor gene has different effects on the risk of diabetic nephropathy in men and women. (2011) (14)
- Renoprotective action of angiotensin-converting enzyme inhibition in diabetes mellitus. (1992) (14)
- Comparing effects of insulin analogues and human insulin on nocturnal glycaemia in hypoglycaemia‐prone people with Type 1 diabetes (2017) (14)
- The increased proximal tubular reabsorption of sodium and water is maintained in long-term insulin-dependent diabetics with early nephropathy. (1989) (14)
- Effect of multiple insulin injections with a pen injector on metabolic control and general well-being in insulin-dependent diabetes mellitus. (1989) (14)
- Dyslipidaemia and cardiovascular disease in non-insulin-dependent diabetic patient with and without diabetic nephropathy. (1994) (14)
- Functional annotations of diabetes nephropathy susceptibility loci through analysis of genome-wide renal gene expression in rat models of diabetes mellitus (2009) (13)
- The natural course of glomerular filtration rate and arterial blood pressure in diabetic nephropathy, and the effect of antihypertensive treatment. (1981) (13)
- Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy. (1999) (13)
- A Comparative Study of Microvascular Complications in Patients with Secondary and Type 1 Diabetes (1990) (13)
- Dual renin-angiotensin system blockade and kidney disease. (2009) (13)
- Relationship between blood pressure and urinary albumin excretion rate in young Danish type 1 diabetic patients: comparison to non-diabetic children. Danish Study Group of Diabetes in Childhood. (1994) (13)
- Controlling hypertension in diabetes (2002) (13)
- The insertion/deletion polymorphism in the angiotensin I-converting enzyme gene predicts the progression of diabetic nephropathy during ACE inhibition in insulin dependent diabetic patients (1995) (13)
- Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria (2021) (13)
- Assessment of glomerular filtration rate in diabetic nephropathy using the plasma clearance of 51Cr-EDTA. (1998) (13)
- Effects of Short‐term Strict Metabolic Control on Kidney Function and Extracellular Fluid Volume in Incipient Diabetic Nephropathy (1989) (12)
- Novel Susceptibility Locus at 22q11 for Diabetic Nephropathy in Type 1 Diabetes (2011) (12)
- Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia—the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) (2016) (12)
- The Trp64Arg amino acid polymorphism of the beta3-adrenergic receptor gene does not contribute to the genetic susceptibility of diabetic microvascular complications in Caucasian type 1 diabetic patients. (1999) (12)
- Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial (2018) (12)
- Antihypertensive treatment postpones end-stage renal failure in diabetic nephropathy. (1988) (12)
- Diabetic nephropathy in 2014: Improved cardiorenal prognosis in diabetic nephropathy (2015) (11)
- Prevalence and causes of microscopic haematuria in Type 1 (insulin-dependent) diabetic patients with persistent proteinuria (1987) (11)
- Endothelial Progenitor Cells in Long-Standing Asymptomatic Type 1 Diabetic Patients with or without Diabetic Nephropathy (2011) (11)
- Sustained postprandial decrease in plasma levels of LDL cholesterol in patients with type‐2 diabetes mellitus (2008) (11)
- A cost analysis of intensified vs conventional multifactorial therapy in individuals with type 2 diabetes: a post hoc analysis of the Steno-2 study (2018) (11)
- Aldosterone synthase (CYP11B2) −344T/C polymorphism is not associated with the initiation and progression of diabetic nephropathy in Caucasian Type 1 diabetic patients (2006) (10)
- Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight (2018) (10)
- Surrogate endpoints and renal protection: focus on microalbuminuria. (1997) (10)
- Glomerular size-and charge selectivity in Type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy (1994) (10)
- Reduced transcapillary escape of albumin during acute blood pressure-lowering in Type 1 (insulin-dependent) diabetic patients with nephropathy (1985) (10)
- N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) predicts the cardio‐renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk (2018) (10)
- The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes (2011) (10)
- [Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication]. (2009) (10)
- Angiotensin-converting enzyme inhibition in diabetic nephropathy. (1989) (10)
- ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. (2017) (10)
- Effects of Dietary Protein on Renal Disease (1997) (9)
- Effects of nisoldipine and lisinopril on microvascular dysfunction in hypertensive Type I diabetes patients with nephropathy. (1998) (9)
- Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease. (2016) (9)
- Hypertension and Diabetes: the Scope of the Problem (2001) (9)
- Monitoring progression of diabetic nephropathy. (1985) (9)
- Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial. (2009) (9)
- Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. (2011) (9)
- Preventing diabetic nephropathy: an audit (2001) (8)
- Hypertension Optimal Treatment (HOT) trial (1998) (8)
- Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria (2011) (8)
- CD2AP is associated with end-stage renal disease in patients with type 1 diabetes (2013) (8)
- The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design (2019) (8)
- The History of Prevention and Treatment of Diabetic Nephropathy (2020) (8)
- A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension (2006) (8)
- Urinary liver-type fatty acid-binding protein (u-LFABP) predicts progression to nephropathy in type 1 diabetic patients. Running title: The tubular marker u-LFABP in type 1 diabetes (2010) (8)
- Morphology of diabetic glomerulopathy and relationship to hypertension. (1989) (8)
- Acquired oligonephropathy and diabetic nephropathy. (1995) (8)
- Intermittent clinical proteinuria and renal function in diabetes (1986) (7)
- [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes]. (2001) (7)
- Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria. (2018) (7)
- Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes. (2016) (7)
- Short-term oral treatment with the angiotensin II receptor antagonist losartan does not improve coronary vasomotor function in asymptomatic type 2 diabetes patients. (2009) (7)
- Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in PatientsWith Type 2 Diabetes andMicroalbuminuria An Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) substudy (2011) (7)
- Low-protein diet and progression of renal disease in diabetic nephropathy (1990) (7)
- Blockade of the renin-angiotensin-aldosterone system and renal protection in diabetes mellitus (2000) (7)
- Protein restriction and renal failure in diabetes mellitus. (1991) (6)
- Aldosterone synthase (CYP11B2)344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy (2006) (6)
- High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes. (2016) (6)
- The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function (2021) (6)
- Lack of familial predisposition to cardiovascular disease in Type 1 (insulin-dependent) diabetic patients with nephropathy (1991) (6)
- Effect of carbonic anhydrase inhibitors on glomerular filtration rate in diabetic nephropathy. (1987) (6)
- Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial (2017) (6)
- Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial (2020) (6)
- Visit‐to‐visit variability of clinical risk markers in relation to long‐term complications in type 1 diabetes (2020) (5)
- The angiotensin‐converting enzyme gene and its inhibition in diabetic nephropathy (1996) (5)
- Autoregulation of Glomerular Filtration Rate in Patients with Diabetes (2000) (5)
- Incident microalbuminuria and complement factor mannan‐binding lectin‐associated protein 19 in people with newly diagnosed type 1 diabetes (2017) (5)
- An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes. (2007) (5)
- The blood‐retinal barrier permeability to fluorescein in juvenile diabetics treated with continuous subcutaneous insulin infusion (1985) (4)
- Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study (2012) (4)
- The effect of short‐term near‐normal blood glucose control on oscillatory potential and macular recovery time in insulin‐dependent diabetic patients with long‐standing metabolic dysregulation (1989) (4)
- Surface Charge of Red Blood Cells in Insulin‐dependent Diabetic Patients with Incipient and Overt Nephropathy (1987) (4)
- Commentary: microalbuminuria: past, present and glorious future. (2014) (4)
- Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease (2020) (4)
- Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials (2018) (4)
- Large Between-Patient Variability in eGFR Decline Before Clinical Trial Enrollment and Impact on Atrasentan's Efficacy - A Post-Hoc Analysis From the SONAR Trial. (2021) (4)
- Comparison of exposure response relationship of atrasentan between North American and Asian populations (2017) (4)
- Converting enzyme-inhibition in diabetic nephropathy. (1989) (4)
- Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin–angiotensin–aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients (2011) (4)
- VITAMIN D LEVELS AND MORTALITY IN TYPE 2 DIABETES: PP.17.143 (2010) (3)
- Renoprotective effects of renin-angiotensin-system inhibitors (2006) (3)
- Abstract 426: The Diovan Reduction Of Proteinutria (Drop) Study: Albuminuria Response to High-Doses Of Valsartan in Type 2 Diabetes Mellitus (2006) (3)
- Effect of ganglionic blockade on endogenous circulating pancreatic polypeptide, vasoactive intestinal polypeptide, substance P, neurotensin and noradrenaline in healthy controls and long-term insulin-dependent diabetic patients. (1986) (3)
- Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial (2021) (3)
- Progression of renal disease (1994) (3)
- Impact of renin angiotensin system blockade on night to day blood pressure ratio in diabetic nephropathy. (2006) (3)
- HYPERTENSION OPTIMAL TREATMENT (HOT) TRIAL. AUTHORS' REPLY (1998) (3)
- Lipoprotein(a)and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria. (2020) (3)
- Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open‐label, crossover trial (2021) (3)
- Prognosis in diabetic nephropathy: Authors' reply (1989) (3)
- The potential for improvement of outcomes by personalized insulin treatment of type 1 diabetes as assessed by analysis of single-patient data from a randomized controlled cross-over insulin trial. (2017) (3)
- Effects of RAS inhibitors on diabetic retinopathy. (2015) (3)
- The Course of Renal Function before and during Antihypertensive Treatment in Diabetic Nephropathy (1988) (3)
- Reduction of urinary connective tissue growth factor by losartan in hypertensive Type 10 diabetic patients with diabetic nephropathy (2004) (2)
- [Significant risk factors for development of microalbuminuria and diabetic nephropathy in patients with non-insulin-dependent diabetes]. (1998) (2)
- [Pioneering research of Niels A. Lassen]. (2007) (2)
- Renin angiotensin system blockade is effective in preventing microalbuminuria in hypertensive but not normotensive people with type 2 diabetes; further analysis of the DIRECT Programme (2010) (2)
- Association between severe diabetic retinopathy and lectin pathway proteins - an 18-year follow-up study with newly diagnosed type 1 diabetes patients. (2020) (2)
- ACE insertion/deletion genotypes and angiotensin II receptor blockade in diabetic nephropathy: is there a light at the end of the tunnel? (2003) (2)
- The canosinase gene (CNDP1) is not a protection factor of diabetic nephropathy in type 1 diabetics (2006) (2)
- Erratum to: Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial (2011) (2)
- Telmisartan vs. enalapril in type 2 diabetes. (2005) (2)
- Concentrations of von Willebrand factor in diabetes (1996) (2)
- CGM-recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia. (2022) (1)
- ACE inhibition in diabetic nephropathy. (1990) (1)
- NT-PROBNP AND HSTNT IMPROVE CARDIOVASCULAR RISK PREDICTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS, CHRONIC KIDNEY OR CARDIOVASCULAR DISEASE OR BOTH (2014) (1)
- Higher plasma advanced glycation endproducts levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study (2010) (1)
- OF POST (2011) (1)
- IMPACT OF TRANSCRIPTION-FACTOR 7-LIKE (TCF7L2) GENE-VARIANTS ON THE RESPONSE TO ANTI-HYPERGLYCAEMIC TREATMENT IN NON-OBESE PATIENTS WITH TYPE-2 DIABETES (T2DM) (2008) (1)
- [Progress in the diagnosis and treatment of pneumocystis carinii pneumonia]. (1976) (1)
- Are human endogenous retroviruses triggers of autoimmune diseases? Unveiling associations of three diseases and viral loci (2015) (1)
- ACTH stimulation test in patients with type 1 diabetes and recurrent severe hypoglycaemia (2015) (1)
- [Insulin pumps and treatment of diabetes]. (2003) (1)
- 40-LB: Association between Complement and Severe Retinal Complications in Type 1 Diabetes—An 18-Year Follow-Up Study (2019) (1)
- Urinary sulphate excretion is a predictor for progression of diabetic nephropathy (2011) (1)
- Antihypertensive drugs and diabetes mellitus. (1987) (1)
- Going out to detect incipient diabetic nephropathy rather than waiting until it has supervened--a reversal in policy. (1996) (1)
- [ACE inhibitors and AT-II antagonists--do they protect against renal disease?]. (2006) (1)
- Tu-W19:4 Impact of metformin versus repaglinide on glycemic regulation and non-glycemic cardiovascular risk-markers in non-obese patients with type-2 diabetes (2006) (1)
- MICROALBUMINURIA IN ESSENTIAL HYPERTENSION AND DIABETES MELLITUS. DISCUSSION (1996) (1)
- SERUM PLACENTAL GROWTH FACTOR (PLGF) PREDICTS ALL-CAUSE AND CARDIOVASCULAR MORTALITY BUT NOT DETERIORATION OF KIDNEY FUNCTION IN TYPE 1 DIABETIC PATIENTS WITH DIABETIC NEPHROPATHY: PP.6.254 (2010) (1)
- Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3‐deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub‐study (2020) (1)
- [Albuminuria and glycemic control. The significance for mortality in non-insulin-dependent diabetes mellitus]. (1996) (1)
- Submaximal dose of trandolapril in the COOPERATE trial (2003) (1)
- Intensiveret multifaktoriel intervention hos patienter med type 2-diabetes mellitus og mikroalbuminuri: Steno-2-studietthe Steno-2 study (1999) (1)
- The selective type A endothelin antagonist atrasentan reduces residual albuminuria in patients with type 2 diabetes and nephropathy (2013) (1)
- Years of Life Gained by Multifactorial Intervention in Patients with Type 2 Diabetes and Microalbuminuria - 21 Years Follow-Up on the Steno-2 Study (2016) (1)
- Clinical trials report (2004) (1)
- Plasma (cid:1) -Defensin Is Associated with Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients (2008) (1)
- Effect of protein kinase C modulators on the leucocyte Na+/H+ antiport in Type 1 (insulin-dependent) diabetic subjects with albuminuria (1991) (0)
- Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia (2023) (0)
- COLLAGEN TYPE III DEGRADATION IS ASSOCIATED WITH DETERIORATION OF KIDNEY FUNCTION IN PATIENTS WITH TYPE 2 DIABETES WITH MICROALBUMINURIA (2018) (0)
- Vitamin D levels and mortality in type 2 diabetes Running title: Vitamin D levels and mortality in type 2 diabetes (2010) (0)
- Influence of Age/Gender/Race on the Efficacy of Ezetimibe/Simvastatin vs. Atorvastatin in Metabolic Syndrome Patients with Moderately High/High CHD Risk (2009) (0)
- The `polypill' to reduce cardiovascular risk: proof of concept Data from the Steno-2 multifactorial intervention study in type 2 diabetes supports the `polypill' strategy to reduce cardiovascular risk (2004) (0)
- Intensified Multifactorial Intervention in Type 2 Diabetes and Microalbuminuria Reduces End Stage Renal Disease and Mortality: 21 Years Follow-Up of the Steno-2 Study (2016) (0)
- Atrasentan in patients with diabetes and chronic kidney disease – Authors' reply (2020) (0)
- SEX-SPECIFIC REGULATION OF URINARY PEPTIDES IN EARLY DIABETIC NEPHROPTHY (2018) (0)
- British Medical Journal (1874) (0)
- Abstract: 582 ATTAINMENT OF SINGLE/DUAL TREATMENT LEVELS FOR LDL-C AND NON-HDL-C, APOB, OR HS-CRP IN PATIENTS WITH METABOLIC SYNDROME (MS): EZETIMIBE(E)/SIMVASTATIN(S) VS ATORVASTATIN(A) (2009) (0)
- 54 EFFECT OF ONE YEAR TREATMENT WITH INSULIN AND ORAL GLUCOSE-LOWERING AGENTS ON LIPID LEVELS IN NON-OBESE PATIENTS WITH TYPE 2-DIABETES (2011) (0)
- Author's reply (1996) (0)
- RNA oxidation and albuminuria in type 1 diabetes patients (2013) (0)
- EURAGEDIC; European consortium for the genetics of diabetic nephropathy: strategy and first results. (2003) (0)
- Pulse pressure partially explains the increased incident cardiovascular disease associated with inflammation in type 1 diabetes: a 12-yr follow-up study (2010) (0)
- University of Groningen N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk Idzerda, (2018) (0)
- Visit-to-Visit Variability of Clinical Risk Markers Is Predictive of Long-Term Complications in Type 1 Diabetes (2020) (0)
- Marker for kidney fibrosis is associated with inflammation and deterioration of kidney function in people with type 2 diabetes and microalbuminuria (2023) (0)
- Abstract: P966 EFFECT OF AGE/GENDER/RACE ON EZETIMIBE/SIMVASTATIN VS. ATORVASTATIN EFFICACY IN METABOLIC SYNDROME PATIENTS WITH MODERATELY HIGH/HIGH CHD RISK (2009) (0)
- Irbesartan was renoprotective in patients with type 2 diabetes, hypertension, and microalbuminuria (2002) (0)
- Estimated GFR: Are There Limits to Its Utility?: Monitoring Kidney Function in Type 2 Diabetic Patients with Incipient and Overt Diabetic Nephropathy. Diabetes Care 29: 1024-1030, 2006. (2006) (0)
- P295 COMPARISON OF METHODS FOR MEASURING LDL-CHOLESTEROL IN THE FASTING AND NONFASTING STATE IN PATIENTS WITH TYPE-2 DIABETES MELLITUS (2010) (0)
- Abstract: P947 EZETIMIBE/SIMVASTATIN (E/S) AND ATORVASTATIN (A) TREATMENT MODIFY APOB, LDL-C, AND NON-HDL-C CORRELATIONS IN METABOLIC SYNDROME (MS) PATIENTS AT MODERATELY HIGH RISK(MHR)/HIGH RISK(HR) FOR CHD (2009) (0)
- Design of clinical trials in proteinuria and progressive renal disease (1992) (0)
- [Salt restriction and blood pressure]. (1999) (0)
- [Low birth weight--increased risk of diabetic nephropathies?]. (1996) (0)
- 908 EFFECTS OF ALISKIREN, IRBESARTAN AND THE COMBINATION ON URINARY LEVELS OF ANGIOTENSINOGEN AND RENIN IN PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND ALBUMINURIA (2012) (0)
- Predictors of 10-year mortality in patients with type 2 diabetes mellitus (2000) (0)
- Results from the ALTITUDE Trial (2012) (0)
- Irbestartan is projected to be cost and life saving in the USA for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria (2003) (0)
- PROactive study (2006) (0)
- 1532-P: Investigating Biomarkers of the Immune Response and Tissue Remodeling in Patients with Type 2 Diabetes with Microalbuminuria (2020) (0)
- Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long‐Term Response to Atrasentan in Patients With Diabetic Kidney Disease (2022) (0)
- 270-OR: Nocturnal Hypoglycemia with Insulin Degludec and Glargine U100 in Patients with Type 1 Diabetes Prone to Severe Nocturnal Hypoglycemia (HypoDeg): A CGM Substudy (2020) (0)
- [Diabetic angiopathies. Vascular function in poor metabolic regulation]. (1979) (0)
- CV4 IRBESARTAN IS PROJECTED TO BE COST AND LIFE SAVING IN THE FRENCH SETTING FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION, AND MICROALBUMINURIA (2003) (0)
- Intensive therapy delayed microvascular complications in patients with type 2 diabetes mellitus and microalbuminuria (1999) (0)
- Abstract 14182: Genome Wide Association Study for High Sensitive Cardiac Troponin T Levels Identifies a Novel Gene in Europeans With Type 1 Diabetes (2020) (0)
- [HbA1 and type 2 diabetes--what is optimal?]. (2005) (0)
- Role of Plasma Homocysteine and Plasminogen Activator Inhibitor-1 in the Progression of Diabetic Nephropathy (2002) (0)
- Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus (2016) (0)
- Diabetes mellitus - clinical studies - 2 (2009) (0)
- Abstract: P1308 EZETIMIBE/SIMVASTATIN (E/S) VS ATORVASTATIN (A) IN PATIENTS WITH HYPERCHOLESTEROLEMIA (HC) AND METABOLIC SYNDROME (METS) GROUPED BY PRESENCE OF ATHEROSCLEROTIC VASCULAR DISEASE (AVD) (2009) (0)
- Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in PatientsWith Type 2 Diabetes andMicroalbuminuria An Irbesartan Microalbuminuria Type 2 Diabetes in Hypertensive Patients ( IRMA ) 2 substudy (2011) (0)
- Effects of insulin administration by pumps on long-term diabetic complications (1985) (0)
- Comparison of Treatment with Insulin Degludec and Glargine U100 in Patients with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycaemia (HypoDeg): A Prospective, Randomized, Open-Label, Crossover Trial (2020) (0)
- Early renin-angiotensin-system intervention is more beneficial than late intervention in delaying end-stage renal disease in type 2 diabetes (2016) (0)
- Bone mineral density, kidney function and arterial stiffness in long-standing type 1 diabetic patients with or without diabetic nephropathy (2012) (0)
- Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes (2018) (0)
- Intensiv multifaktoriel behandling og mortalitet ved type 2- diabetes - Sekundærpublikation (2008) (0)
- Effect of Metabolic Syndrome Factors and Insulin Resistance on Ezetimibe/Simvastatin and Atorvastatin Treatment Efficacy in Patients with Metabolic Syndrome and Moderately High/High CHD Risk (2009) (0)
- Diabetic Nephropathy. In:Brenner & Rector's The Kidney, 10th editionElsevierISBN: 978-1-4557-4836-5, vol1, 1283-132. Rossing P, Fioretto p, Felt-Rasmussen B, Parving H-H. (2015) (0)
- 3141 Cataract and diabetes: A surgical model (1995) (0)
- Chronic low-grade inflammation mediates the association between body mass index and pulse pressure in women with type 1 diabetes: a 20-yr longitudinal study (2008) (0)
- Serum Uric Acid as aN ew Player in the Development of Diabetic Nephropathy (2011) (0)
- EFFECTS OF DIETARY PROTEIN ON RENAL DISEASE. AUTHORS'REPLY (1997) (0)
- Left ventricular function, mass, and volumes in type 1 diabetic patients – and relation to NT-proBNP (2008) (0)
- Diabetic kidney disease: collaboration is the key (2012) (0)
- SNP in GWAS hotspot on chromosome 9p21 confers susceptibility to diabetic nephropathy in type 1 diabetes: Oral Presentation (2011) (0)
- PDB33 COST-CONSEQUENCE ANALYSIS OF SCREENING AND OPTIMIZED TREATMENT OF NEPHROPATHY IN HYPERTENSIVE PATIENTS WITH TYPE-2 DIABETES INA FRENCH SETTING (2005) (0)
- [Splenectomy in chronic idiopathic thrombocytopenia]. (1977) (0)
- University of Groningen Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight Koomen, (2018) (0)
- [Risk factors for the development of microalbuminuria in type 1 diabetes: an incidence cohort study--a secondary publication]. (2005) (0)
- Irbesartan treatment does not influence plasma levels of the advanced glycation end products CML and CEL in patients with type 2 diabetes and microalbuminuria. An IRMA2 substudy (2010) (0)
- [New aspects in treatment and pathogenesis of mountain-sickness]. (1971) (0)
- Endothelial dysfunction and low-grade inflammation precede the increase in urinary albumin excretion in type 1 diabetes: a 20-yr longitudinal study (2008) (0)
- The 'polypill' to reduce cardiovascular risk : proof of concept : healthcare management (2005) (0)
- 237-OR: Beneficial Impact of Intensified Multifactorial Intervention on Stroke—The Steno-2 Study (2019) (0)
- Diabetic nephropathy: Pathophysiology, hypertension and treatment. (1989) (0)
- Acute Modulation of Renal Function in Microalbuminuric and Macroalbuminuric Insulin-Dependent Diabetic Patients (1988) (0)
- Low-grade inflammation and endothelial dysfunction precede the increase in pulse pressure in type 1 diabetes: a 20-yr longitudinal study (2009) (0)
- Higher plasma sRAGE levels are associated with incident cardiovascular morbidity and mortality as well as all-cause mortality in type 1 diabetes: a 12-yr follow-up study (2009) (0)
- Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria (2011) (0)
- 269-OR: Effect of Insulin Degludec on Frequency of Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia: The HypoDeg Trial (2020) (0)
- Prevention and treatment of renal and cardiovascular disease in diabetes: new aspects (2013) (0)
- 131-OR: ADA Presidents’ Select Abstract: Effect of Insulin Degludec vs. Insulin Glargine U100 on Occurrence of Nocturnal Hypoglycemia Assessed by Nocturnal Plasma Glucose Profiles in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia (2021) (0)
- PO22-724 IMPACT OF METFORMIN VERSUS REPAGLINIDE ON POSTPRANDIAL GLYCAEMIA AND PLASMA LIPOPROTEINS IN NON-OBESE PATIENTS WITH TYPE-2 DIABETES MELLITUS (T2DM) (2007) (0)
- Prevention and treatment of diabetic nephropathy with blood pressure lowering drugs (1996) (0)
- Abstract: 31 EZETIMIBE/SIMVASTATIN (E/S) VS ATORVASTATIN (A) IN METABOLIC SYNDROME (MS) PATIENTS WITH HYPERCHOLESTEROLEMIA (HC) (2009) (0)
- Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure. (2022) (0)
- Abstract: P967 INFLUENCE OF METABOLIC SYNDROME (MS) FACTORS AND INSULIN RESISTANCE (IR) ON EZETIMIBE (E)/SIMVASTATIN (S) AND ATORVASTATIN (A) EFFICACY IN PATIENTS WITH MS AND MODERATELY HIGH (MH) OR HIGH (H) CHD RISK (2009) (0)
- Determinants of progression in diabetic nephropathy with and without antihypertensive treatment (1992) (0)
- Comparison of insulin degludec and glargine U100 in patients with type 1 diabetes prone to severe nocturnal hypoglycaemia (2020) (0)
- Clinical trials report. angiotensin-converting enzyme inhibition in diabetes: above and beyond the beneficial effect of blood pressure? (2004) (0)
- The Thioredoxin System in Diabetic Nephropathy (2008) (0)
- Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients - interaction with ACE insertion/deletion polymorphism. Commentary (2006) (0)
- Abstract 14369: Long-term Reduction in Coronary Artery Disease and Stroke With 7,8 Years of Intensified, Multifactorial Intervention in Patients With Type 2 Diabetes and Microalbuminuria in the Steno-2 Study (2016) (0)
- Issue Highlights. (2015) (0)
- Genetic studies of diabetic nephropathy in three European populations (EURAGEDIC consortium): analyses of 14 candidate genes on chromosome 3q (2005) (0)
- 2-OR: Impact of N Terminal Pro B-Type Natriuretic Peptide and High Sensitivity Cardiac Troponin on the Prediction of Death and Cardiovascular Events in High-Risk Patients with Type 2 Diabetes (2020) (0)
- Mannanbindende lektin og mortalitet hos patienter med type 2-diabetes--sekundaerpublikation (2009) (0)
- Efficacy and Safety of Ezetimibe/Simvastatin vs. Atorvastatin in Patients with Hypercholesterolemia, Metabolic Syndrome, and Atherosclerotic Vascular Disease (2009) (0)
- Prognosis in diabetic nephropathy. (1989) (0)
- Monitoring kidney function in diabetic nephropathy (1989) (0)
- Data from the Steno-2 multifactorial intervention study in type 2 diabetes supports the 'polypill' strategy to reduce cardiovascular risk (2004) (0)
This paper list is powered by the following services:
